Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Obstet Gynecol ; 200(5): 516.e1-6, 2009 May.
Article in English | MEDLINE | ID: mdl-19268879

ABSTRACT

OBJECTIVE: We previously demonstrated that omega-3 fatty acids (OM-3FAs) have definitive inhibitory effects on ovarian cancer cell lines. We sought to determine whether the inhibitory effects of OM-3FAs were mediated by the transforming growth factor (TGF)-beta1 signaling pathway. STUDY DESIGN: Ovarian cancer cell lines were grown at 37 degrees C in 5% CO(2) and treated with OM-3FAs, omega-6 fatty acids, and control at different concentrations for 24-72 hours. Enzyme-linked immunosorbent assay (ELISA) assay and Western blot analysis were used to measure TGF-beta1, phosphorylated mothers against decapentaplegic (Smad)-3 and p21 protein levels. RESULTS: An ELISA assay demonstrated that OM-3FA treatment increased TGF-beta1 in all 3 Hey cell lines (P < .05). In both SKOV-3 and OVCAR-3 cells, TGF-beta1 levels were not significantly increased. Western blots confirmed increases in TGF-beta1, Smad-3 and p21 protein levels in Hey and HeyC2 but not SKOV-3 and OVCAR-3 cells. CONCLUSION: OM-3FAs increased the level of TGF-beta1, Smad-3, and p21 protein in ovarian cancer cells known to be more sensitive to their inhibitory effect.


Subject(s)
Fatty Acids, Omega-3/pharmacology , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/prevention & control , Signal Transduction/drug effects , Transforming Growth Factor beta1/metabolism , Benzamides , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Fatty Acids, Omega-6/pharmacology , Female , Humans , Ovarian Neoplasms/diet therapy , Phosphorylation/drug effects , Smad3 Protein/metabolism , Tumor Suppressor Protein p53/metabolism
2.
J Am Soc Nephrol ; 11(3): 394-402, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10703663

ABSTRACT

The aim of this study was to define mechanisms involved in the luminal uptake of inorganic mercury in the kidney using isolated perfused straight (S2) segments of the proximal tubule. When mercuric conjugates of glutathione (GSH), cysteinylglycine. or cysteine (containing 203Hg2+) were perfused through the lumen, the rates of luminal disappearance flux (JD) of inorganic mercury were approximately 39, 53, and 102 fmol/min per' min, respectively. Thus, the rates of luminal uptake of mercury are greater when the mercury is in the form of a mercuric conjugate of cysteine than in the form of a mercuric conjugate of cysteinylglycine or GSH. Addition of acivicin to the perfusate, to inhibit activity of the y-glutamyltransferase, caused significant reductions in the J,, for mercury in tubules perfused with mercuric conjugates of GSH. Addition of cilastatin, an inhibitor of dehydropeptidase- l (cysteinylglycinase) activity, caused significant reductions in the uptake of mercury in tubules perfused with mercuric conjugates of cysteinylglycine. These findings indicate that a significant amount of the luminal uptake of mercury, when mercuric conjugates of GSH are present in the lumen, is dependent on the activity of both y-glutamyltransferase and cysteinylglycinase. Finally, the JD for mercury in tubules perfused with mercuric conjugates of cysteine was reduced by approximately 50% when 3.0 mM L-lysine or 5.0 mM cycloleucine was added to the perfusate. It is concluded that these findings indicate that at least some of the luminal uptake of mercuric conjugates of cysteine occurs at the site of one or more amino acid transporters via a mechanism involving molecular homology.


Subject(s)
Kidney Tubules, Proximal/metabolism , Mercury/pharmacokinetics , Animals , Cilastatin/pharmacology , Cysteine/physiology , Dipeptidases/antagonists & inhibitors , Dipeptidases/physiology , Enzyme Inhibitors/pharmacology , Female , Glutathione/pharmacokinetics , In Vitro Techniques , Isoxazoles/pharmacology , Kidney Tubules, Proximal/drug effects , Protease Inhibitors/pharmacology , Rabbits , Sequence Homology, Amino Acid , gamma-Glutamyltransferase/antagonists & inhibitors , gamma-Glutamyltransferase/physiology
SELECTION OF CITATIONS
SEARCH DETAIL